Related Experiment Video

Updated: Jun 21, 2026

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model
05:58

Mouse Electroacupuncture Fixation Device Fabrication for Electroacupuncture Pretreatment in Diabetic Cardiomyopathy Mouse Model

Published on: April 18, 2025

Do cardioselective beta-adrenoceptor antagonists reduce mortality in diabetic patients with congestive heart failure?

Usha Subramanian1, Masoor Kamalesh, M'hamed Temkit

  • 1Krannert Institute of Cardiology and Roudebush Veterans Affairs Medical Center, Indiana University Medical Center, Indianapolis, Indiana 46202, USA.

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
|August 7, 2009
PubMed

Insights

Diabetic patients with congestive heart failure (CHF) may not experience the same survival benefits from cardioselective beta-blockers (CSB) as non-diabetic patients. Further research is needed to confirm these findings in diabetes mellitus populations.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • The benefits of cardioselective beta-adrenoceptor antagonists (CSB) in patients with congestive heart failure (CHF) and diabetes mellitus are not well-established.
  • Understanding differential treatment effects is crucial for optimizing patient care.

Purpose of the Study:

  • To investigate whether diabetic patients with CHF receive the same mortality benefit from CSB therapy as non-diabetic patients.
  • To compare survival outcomes stratified by diabetes status and CSB treatment.

Main Methods:

  • A post hoc analysis of a randomized controlled trial involving 412 patients with CHF followed for 5 years.
  • Propensity-score analysis was used to balance covariates due to the observational nature of CSB use.
  • A multivariate Cox proportional hazards model compared survival between diabetic and non-diabetic patients receiving CSB therapy versus those who were not.

Main Results:

  • CSB therapy was associated with improved survival in non-diabetic patients (hazard ratio 0.60; p = 0.054).
  • The survival benefit of CSB therapy was not statistically significant in diabetic patients with CHF.
  • Out of 412 patients, 222 had diabetes, and 186 died within 5 years.

Conclusions:

  • Diabetic patients with CHF may not derive the same mortality benefits from CSB therapy as their non-diabetic counterparts.
  • These findings suggest a potential difference in CSB efficacy based on diabetes status in CHF patients.
  • Further prospective studies are warranted to validate these observations.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...